Collaborative Arrangements (Tables)

6 Months Ended

Jun. 30, 2021

Collaborative Arrangements [Abstract]

Summarized financial information related to this collaboration is as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
($ in millions)	2021		2020		2021		2020
Alliance revenue - Lynparza	$	248	$	178	$	475	$	323
Alliance revenue - Koselugo	8		—		14		—
Total alliance revenue	$	256	$	178	$	489	$	323

Cost of sales (1)	42		137		84		164
Selling, general and administrative	43		39		83		72
Research and development	31		37		60		73

($ in millions)					June 30, 2021		December 31, 2020
Receivables from AstraZeneca included in Other current assets					$	258	$	215
Payables to AstraZeneca included in Accrued and other current liabilities (2)					418		423

(1) Represents amortization of capitalized milestone payments.

(2) Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
($ in millions)	2021		2020		2021		2020
Alliance revenue - Lenvima	$	181	$	151	$	310	$	279

Cost of sales (1)	47		135		94		170
Selling, general and administrative	31		19		54		31
Research and development	57		56		121		120

($ in millions)					June 30, 2021		December 31, 2020
Receivables from Eisai included in Other current assets					$	212	$	157
Payables to Eisai included in Accrued and other current liabilities (2)					600		335
Payables to Eisai included in Other Noncurrent Liabilities (3)					—		600

(1) Represents amortization of capitalized milestone payments.

(2) Includes accrued milestone and future option payments.

(3) Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
($ in millions)	2021		2020		2021		2020
Alliance revenue - Adempas/Verquvo	$	74	$	79	$	149	$	133
Net sales of Adempas recorded by Merck	74		57		129		113
Net sales of Verquvo recorded by Merck	1		—		1		—
Total sales	$	149	$	136	$	279	$	246

Cost of sales (1)	39		28		229		57
Selling, general and administrative	32		17		58		28
Research and development	13		16		20		41

($ in millions)					June 30, 2021		December 31, 2020
Receivables from Bayer included in Other current assets					$	65	$	65
Payables to Bayer included in Other Noncurrent Liabilities (2)					400		—

(1) Includes amortization of intangible assets. Amount in the first six months of 2021 includes $153 million of cumulative amortization as noted above.

(2) Represents accrued milestone payment.